Contact Us
Drug Search Results
More Filters [+]

Tosedostat

Alternative Names: tosedostat, chr-2797
Latest Update: 2023-09-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: APM1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chroma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tosedostat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts|Preleukemia|Adenocarcinoma|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Myelodysplastic Syndrome|Leukemia, Plasma Cell|Multiple Myeloma|Leukemia

Phase 1: Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Preleukemia|Myelodysplastic Syndrome|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2006-7041-83/hah

N/A

Not yet recruiting

Surgical Wound Infection

2020-05-04

NCI-2018-01817

P1

Terminated

Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia

2019-07-04

MUK three

P2

Completed

Multiple Myeloma

2017-10-30

IST-CTI-MDS

P2

Completed

Preleukemia|Myelodysplastic Syndrome

2017-10-25

Recent News Events

Date

Type

Title

01/01/2022

PubMed

 Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention.

07/01/2021

PubMed

 A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.

02/07/2021

PubMed

 Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions